Payers Expect Clearer Demonstration of Health Technology Benefits
Sweden and Finland are leaders in developing and applying health technology and provide ideal environments for conducting Health Technology Assessments (HTA) for medical devices.
Risk-Sharing Agreements
Comprehensive solutions for implementing risk-sharing models.
Confidential price agreements have become more widespread with regard to hospital medicines, while decisions on conditional reimbursement are becoming more established in the price and reimbursement processes of outpatient medicines.
Confidential agreements can be risk-sharing agreements (for example, pay for performance, conditional treatment continuation, or other contracts that reward the patient for the benefit of the treatment) or a method for sharing and managing uncertainty about the cost and effectiveness of medicines to the satisfaction of both parties. This will eventually make the medicine available to those patients who will benefit from it.
”Risk sharing agreements aim to solve the classic pharmaceutical sales dilemma of who bears the risk of effectiveness and cost effectiveness related to the purchasing and using of medicines.”
“We at Medaffcon execute risk-sharing agreements between the parties, ensuring that the agreements are operational and mutually beneficial. ”
In our service concept we:
- determine the optimal method for evaluating the medicine and, if necessary, take care of the evaluation process to ensure a medicine’s rapid commissioning decision
- design an optimal price agreement from the perspectives of both parties
- when necessary, evaluate the cost-effectiveness of the selected model and the budget impact for both parties
- are responsible for the agreement negotiations with hospitals, providing a neutral expert view on what sort of a model could be acceptable for both parties
- organize the transfer of money and goods on a “turn-key” principle, regardless of whose distribution service is used (e.g. Tamro, Oriola, Magnum)
Contact us!
A successful risk-sharing agreement:
- helps the parties to work in closer cooperation in the evaluation and implementation of a new form of treatment
- helps all parties evaluate and set the value for a new or existing form of treatment in a more precise manner
- ensures optimal treatment pricing to satisfy both parties, for example in cases where the effectiveness and benefits of new forms of treatments are still uncertain for the patient – and it enables the faster implementation and use of such treatment with a more sustainable pricing model
- enables faster market access to a new form of treatment
Typical project phases
Related articles
-
-
Medaffcon’s Patient Dynamics Tool Helps Focus and Find the Right Actions
Are you employed in the pharmaceutical industry and seeking insights into your product's position within the Finnish market? Then Patient Dynamics is the ideal tool for you. Developed by Medaffcon, Patient Dynamics caters to the needs of pharmaceutical companies by providing precise information for sales and marketing decision-making.
-
Renewable drug therapy challenges the current complex drug evaluation system
“Renewable drug therapy challenges the current complex drug evaluation system,” states Lauri Pelkonen, a leading expert at the Ministry of Social Affairs and Health (STM). For this reason, the evaluation activity is being reformed to better respond to changes in the operating environment.
